Bernard Fisher says his life's work has been emphasizing the importance of biological testing in clinical trials. As the newly elected president of the American Society of Clinical Oncology (ASCO), he says he hopes to influence oncologists worldwide to explore the benefits of these trials as testing mechanisms.

Testing scientific hypotheses in a clinical setting is, according to Fisher, a superior way to search for new medical therapies as well as fortifying old biological principles.

"The main reason for my affiliation with ASCO," Fisher says, "is that my whole life has been spent translating science into clinical practice. Through this organization, I hope to be a force in continuing to do this in a bigger sphere.

"Basically, this is a good forum to advance research that appears in an intellectual scientific aura into practical clinical oncology."

A good example of this, says Fisher—who is a Distinguished Service Professor of surgery...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?